Related Experiment Video
Updated: Sep 19, 2025
![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)
Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
Published on: February 17, 2022
A ROS-Responsive Dual-Targeting Drug Nanocarrier Serving as a GSI Synergist and Ferroptosis Sensitizer for T-Cell
Ruinan Jia1, Yang Liu2, Jilong Xiao1
1Department of Hematology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, 250012, P. R. China.
Abstract:
T-cell acute lymphoblastic leukemia (T-ALL) is a highly aggressive hematological malignancy for which targeted therapies remain underdeveloped. Oncogenic mutations in Notch1 occur in up to 75% of T-ALL patients. Although γ-secretase inhibitors (GSIs) can block Notch1 activation, their clinical application is limited by side effects and reduced sensitivity. Here, a self-assembling, reactive oxygen species (ROS)-responsive nanotherapeutic strategy-PHD/G-NPs-co-loaded with GSI and controlled released dihydroartemisinin (DHA), and modified with a CD38 antibody is reported. The CD38 antibody specifically targets T-ALL cells, while GSI selectively inhibits Notch1, resulting in a dual-targeting approach. GSI is released first, inhibiting Notch1 activation and inducing the death of a subset of T-ALL cells. To eliminate semi-quiescent T-ALL cells that escape initial therapy by elevating ROS levels, a ROS-sensitive DHA delivery system is employed to enhance ferroptosis and boost GSI efficacy. After elucidating the mechanism of action of PHD/G-NPs in T-ALL cells, PHD/G-NPs are combined with αPD-1, which triggers an anti-tumor immune response in vivo. This dual-targeting strategy using CD38-modified PHD/G-NPs enables controlled drug release, enhances ferroptosis, mitigates GSI-induced gastrointestinal toxicity, and improves therapeutic efficacy. This nanomedical approach offers a novel strategy for targeted T-ALL treatment.
Insights
A novel nanotherapy targets T-cell acute lymphoblastic leukemia (T-ALL) by combining Notch1 inhibition with ferroptosis. This dual-action approach enhances treatment efficacy and reduces side effects for aggressive T-ALL.
Area of Science:
- Biomedical Engineering
- Nanomedicine
- Oncology
Background:
- T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive cancer with limited targeted therapies.
- Notch1 mutations are common in T-ALL, but Notch1 inhibitors have clinical limitations.
- Existing therapies struggle to eliminate semi-quiescent T-ALL cells.
Purpose of the Study:
- To develop a novel nanotherapeutic strategy for T-ALL treatment.
- To create a dual-targeting approach combining Notch1 inhibition and ferroptosis.
- To improve drug delivery and reduce side effects associated with T-ALL therapies.
Main Methods:
- Engineered self-assembling, ROS-responsive nanotherapeutics (PHD/G-NPs) co-loaded with GSI and DHA.
- Modified nanoparticles with a CD38 antibody for targeted delivery to T-ALL cells.
- Investigated dual-drug release, ferroptosis induction, and combination therapy with αPD-1.
Main Results:
- The CD38 antibody specifically targeted T-ALL cells.
- Sequential release of GSI and DHA effectively inhibited Notch1 and induced ferroptosis.
- The nanotherapy demonstrated improved efficacy and reduced gastrointestinal toxicity in vivo.
- Combination with αPD-1 triggered an anti-tumor immune response.
Conclusions:
- CD38-modified PHD/G-NPs offer a promising dual-targeting strategy for T-ALL.
- This nanomedical approach enables controlled drug release and enhanced therapeutic outcomes.
- The strategy shows potential for overcoming limitations of current T-ALL treatments.
